Cargando…
The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
Autores principales: | Lancaster, Victoria, Richardson, Marina, Beaudoin, Francesca L, Synnott, Patricia G, Rind, David M, Herce-Hagiwara, Belén, Campbell, Jon D, Pearson, Steven D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372978/ https://www.ncbi.nlm.nih.gov/pubmed/36282936 http://dx.doi.org/10.18553/jmcp.2022.28.11.1316 |
Ejemplares similares
-
Zynteglo: Betibeglogene autotemcel – An innovative therapy for β- thalassemia patients
por: Asghar, Adam Ali, et al.
Publicado: (2022) -
Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia
por: Kansal, Anuraag R., et al.
Publicado: (2021) -
Medications for obesity management: Effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Atlas, Steven J, et al.
Publicado: (2023) -
The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Fazioli, Katherine T., et al.
Publicado: (2020) -
The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)